Abstract
AbstractChronic inflammation during many diseases is associated with bone loss. While interferons (IFNs) are often inhibitory to osteoclast formation, the complex role that IFN and interferon-stimulated genes (ISGs) play in osteoimmunology during inflammatory diseases is still poorly understood. We show that mice deficient in IFN signaling components including IFN alpha and beta receptor 1 (IFNAR1), interferon regulatory factor 1 (IRF1), IRF9, and STAT1 each have reduced bone density and increased osteoclastogenesis compared to wild type mice. The IFN-inducible guanylate-binding proteins (GBPs) on mouse chromosome 3 (GBP1, GBP2, GBP3, GBP5, GBP7) are required to negatively regulate age-associated bone loss and osteoclastogenesis. Mechanistically, GBP2 and GBP5 both negatively regulate in vitro osteoclast differentiation, and loss of GBP5, but not GBP2, results in greater age-associated bone loss in mice. Moreover, mice deficient in GBP5 or chromosome 3 GBPs have greater LPS-mediated inflammatory bone loss compared to wild type mice. Overall, we find that GBP5 contributes to restricting age-associated and inflammation-induced bone loss by negatively regulating osteoclastogenesis.
Funder
U.S. Department of Health & Human Services | National Institutes of Health
American Lebanese Syrian Associated Charities
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference74 articles.
1. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337–342 (2003).
2. Abu-Amer, Y., Ross, F. P., Edwards, J. & Teitelbaum, S. L. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J. Clin. Investig. 100, 1557–1565 (1997).
3. Amarasekara, D. S. et al. Regulation of osteoclast differentiation by cytokine networks. Immune Netw. 18, e8 (2018).
4. Bi, H. et al. Key triggers of osteoclast-related diseases and available strategies for targeted therapies: a review. Front. Med. 4, 234 (2017).
5. Roderick, M. R., Shah, R., Rogers, V., Finn, A. & Ramanan, A. V. Chronic recurrent multifocal osteomyelitis (CRMO) – advancing the diagnosis. Pediatr. Rheumatol. 14, 47 (2016).
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献